The FDA said the recall affects several drugs products containing the active ingredient valsartan following the detection of an impurity found in the products. Valsartan is used to treat high blood pressure and heart failure. However, not all medication containing the ingredient is affected by the recall.
The U.S. recall includes drug products containing a version of valsartan made by Major Pharmaceuticals, Solco Healthcare, and Teva Pharmaceuticals Industries Ltd. Drug products containing valsartan/hydrochlorothiazide (HCTZ) made by Solco Healthcare and Teva Pharmaceuticals Industries Ltd. are also on the recall list.
“We have carefully assessed the valsartan-containing medications sold in the United States, and we’ve found that the valsartan sold by these specific companies does not meet our safety standards. This is why we’ve asked these companies to take immediate action to protect patients,” said Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research.
The agency said the review into drugs contamination is ongoing, with a focus to investigate levels of NDMA in the recalled products, assess the possible effect on patients who have been taking them, and determine what measures can be taken to reduce or eliminate the impurity from future batches produced by the companies.
“The FDA is committed to maintaining our gold standard for safety and efficacy. That includes our efforts to ensure the quality of drugs and the safe manner in which they’re manufactured,” said FDA Commissioner Scott Gottlieb.
“When we identify lapses in the quality of drugs and problems with their manufacturing that have the potential to create risks to patients, we’re committed to taking swift action to alert the public and help facilitate the removal of the products from the market.
“As we seek the removal of certain drug products today, our drug shortages team is also working hard to ensure patients’ therapeutic needs are met in the United States with an adequate supply of unaffected medications.”
The FDA is advising patients who are taking the recalled valsartan-containing medicines to continue taking their medicine until they have a replacement product.
The FDA also advises patients to contact their healthcare professional if their medicine is included in the recall to discuss their treatment options.